» Articles » PMID: 20055705

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides As a Therapeutic Platform

Overview
Publisher Annual Reviews
Specialties Pharmacology
Toxicology
Date 2010 Jan 9
PMID 20055705
Citations 566
Authors
Affiliations
Soon will be listed here.
Abstract

Dramatic advances in understanding of the roles RNA plays in normal health and disease have greatly expanded over the past 10 years and have made it clear that scientists are only beginning to comprehend the biology of RNAs. It is likely that RNA will become an increasingly important target for therapeutic intervention; therefore, it is important to develop strategies for therapeutically modulating RNA function. Antisense oligonucleotides are perhaps the most direct therapeutic strategy to approach RNA. Antisense oligonucleotides are designed to bind to the target RNA by well-characterized Watson-Crick base pairing, and once bound to the target RNA, modulate its function through a variety of postbinding events. This review focuses on the molecular mechanisms by which antisense oligonucleotides can be designed to modulate RNA function in mammalian cells and how synthetic oligonucleotides behave in the body.

Citing Articles

RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.

Mohammadi A, Karimian A, Shokri K, Mohammadi A, Hazhir-Karzar N, Bahar R J Cardiovasc Transl Res. 2025; .

PMID: 40080261 DOI: 10.1007/s12265-025-10603-4.


Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.


New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.

Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E Curr Res Toxicol. 2025; 8:100222.

PMID: 40027547 PMC: 11872130. DOI: 10.1016/j.crtox.2025.100222.


Integrating Machine Learning-Based Approaches into the Design of ASO Therapies.

Leckie J, Yokota T Genes (Basel). 2025; 16(2).

PMID: 40004514 PMC: 11855077. DOI: 10.3390/genes16020185.


Genetic therapies for movement disorders - current status.

Sartorelli J, Ng J, Rahim A, Waddington S, Kurian M J Neurol. 2025; 272(3):220.

PMID: 39985571 PMC: 11846774. DOI: 10.1007/s00415-025-12940-5.